According to the Alzheimer’s Association, an estimated 5.8 million Americans of all ages are living with Alzheimer’s in 2019. Despite its wide reach, there have not been any new drugs approved to slow the impact of the disease in 16 years. That’s where Alzheon comes in. The company is in the advanced stages of clinical testing for an oral pill with the potential to slow or stop the progression of the disease. We spoke to Dr. Martin Tolar, CEO at Alzheon about this potential new treatment.